Composition for preventing or treating obesity containing 4-BPCA and uses thereof

The 4-BPCA composition addresses the challenge of obesity by inhibiting adipocyte differentiation and lipid accumulation through downregulating key adipogenic factors, offering a therapeutic and preventive solution for obesity and related metabolic disorders.

KR103045711B1Active Publication Date: 2026-11-06IND ACADEMIC COOPERATION FOUND KEIMYUNG UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
KR1020240089747
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2026-11-06
Estimated Expiration
2044-07-08

AI Technical Summary

Technical Problem

Existing treatments for obesity lack effective compounds that inhibit adipocyte differentiation and lipid accumulation, which are key factors in obesity development and related metabolic disorders.

Method used

A pharmaceutical composition comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or its pharmaceutically acceptable salts is developed to inhibit fat cell differentiation and lipid accumulation by reducing the expression of key transcription factors and proteins involved in adipogenesis.

Benefits of technology

4-BPCA effectively inhibits lipid accumulation and adipocyte differentiation, providing a potential therapeutic and preventive agent for obesity and related metabolic disorders by downregulating C/EBP-α, PPAR-γ, FAS, and perilipin A, thereby reducing obesity-related symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024073865616-PAT00007_ABST
    Figure 112024073865616-PAT00007_ABST
Patent Text Reader

Abstract

One aspect relates to a composition for the prevention or treatment of obesity comprising 4-BPCA and the use thereof. According to one aspect, 4-BPCA can inhibit the differentiation of adipocytes, inhibit lipid accumulation within adipocytes, and inhibit the expression of C / EBP-α, PPAR-γ, FAS, perilipin A, and RBP-4. Therefore, the 4-BPCA can be usefully utilized for the prevention or treatment of obesity.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] One example of the present invention relates to a composition for the prevention or treatment of obesity comprising 4-BPCA and the use thereof. Background Technology

[0002] Obesity is a medical condition characterized by the excessive accumulation of body fat that threatens an individual's health. It is a complex and multifactorial disease caused by genetic, environmental, behavioral, and hormonal factors. Obesity is associated with an increased risk of developing various conditions, including type 2 diabetes, hypertension, cardiovascular disease, stroke, certain types of cancer, and musculoskeletal disorders. Furthermore, it can lead to psychological problems such as depression and low self-esteem. There is a significant link between obesity and impaired lipolysis regulation.

[0003] Adipogenesis is the process by which preadipocytes or adipocyte progenitor cells (APCs) differentiate into mature adipocytes. This process is essential for the development and maintenance of adipose tissue, which is important for energy homeostasis and metabolism. Subsequently, adipose tissue and adipocytes secrete adipokines that serve as energy depots for triglycerides and regulate various physiological processes in the body. Among the secreted adipokines, the excessive or unbalanced production of leptin, adiponectin, and retinol-binding protein-4 (RBP-4) is associated with obesity and related diseases.

[0004] It has been revealed that adipogenesis is regulated by the coordinated action of several transcription factors, including CCAAT / enhancer-binding protein (C / EBP), peroxisome proliferator-activated receptor (PPAR), and signal transducers and activators of transcriptions (STAT). There is also evidence that several other factors, including fatty acid synthase (FAS) and perilipin A, play essential roles in adipogenesis and contribute to the regulation of adipocyte differentiation, lipid (fatty acid) synthesis, and lipid stability.

[0005] Caffeic acid (CA) is a phenolic compound widely found in various fruits and coffee beans, and is one of the major products consumed in the Western diet. CA and its natural derivatives, including caffeic acid phenethyl ester (CAPE), possess anti-inflammatory, antioxidant, anticancer, and anti-adipogenesis properties. Recently, utilizing diversity-oriented synthesis, a series of CA derivatives including (E)-N-(4-butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide (4-BPCA) have been generated, and anti-melanogenesis and anti-melanoma effects have been reported. However, the anti-obesity effects and mechanisms of 4-BPCA in adipocytes are not yet known. Prior art literature

[0006] Korean Registered Patent 10-1778082 The problem to be solved

[0007] One aspect provides a pharmaceutical composition for the prevention or treatment of obesity comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a pharmaceutically acceptable salt thereof as an active ingredient.

[0008] Another aspect is to provide a pharmaceutical preparation for the prevention or treatment of obesity comprising the above-mentioned pharmaceutical composition.

[0009] Another aspect is to provide a health functional food composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0010] Another aspect is to provide a quasi-drug composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0011] Another aspect is to provide a cosmetic composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0012] Another aspect is to provide a method for preventing or treating obesity, comprising the step of administering 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) to an individual.

[0013] Another aspect is to provide the use of 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) for the manufacture of drugs for the prevention or treatment of obesity.

[0014] Another aspect is providing the use of 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) for the prevention or treatment of obesity. means of solving the problem

[0015] To achieve the above objective, a pharmaceutical composition for the prevention or treatment of obesity is provided, comprising as an active ingredient 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof.

[0016] [Chemical Formula 1]

[0017]

[0018] In one embodiment of the present invention, the composition may inhibit the differentiation of fat cells.

[0019] In another embodiment of the present invention, the composition may inhibit lipid accumulation within fat cells.

[0020] In another embodiment of the present invention, the composition may reduce the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, FAS and perilipin A, RBP-4 during the process of adipocyte differentiation.

[0021] In addition, the present invention provides a pharmaceutical preparation for the prevention or treatment of obesity comprising the above pharmaceutical composition.

[0022] In one embodiment of the present invention, the formulation may be an injectable formulation, an infusion formulation, a spray formulation, a liquid formulation, or a patch formulation.

[0023] In addition, the present invention provides a health functional food composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0024] In one embodiment of the present invention, the composition may inhibit the differentiation of fat cells.

[0025] In another embodiment of the present invention, the composition may inhibit lipid accumulation within fat cells.

[0026] In another embodiment of the present invention, the composition may reduce the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, FAS and perilipin A, RBP-4 during the process of adipocyte differentiation.

[0027] In addition, the present invention provides a quasi-drug composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0028] In one embodiment of the present invention, the composition may be formulated into an external preparation, a powder, a disinfectant, a toothpaste, an ointment, a lotion, an internal preparation, a wet wipe, a spray patch, a bandage, or a patch.

[0029] In addition, the present invention provides a cosmetic composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0030] In one embodiment of the present invention, the composition may be formulated as a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, a lotion, an essence, a pack, a skin adhesive patch, a skin adhesive gel, a powder, an ointment, a paste, a gel, a suspension, an emulsion, a spray, a cosmetic liquid, or a capsule. Effects of the invention

[0031] The inventors confirmed that 4-BPCA strongly inhibits lipid accumulation during the adipocyte differentiation process of 3T3-L1 preadipocytes and hASCs, and that the lipid-reducing effect of 4-BPCA on 3T3-L1 cells and hASCs is due to the downregulation of the expression of C / EBP-α, PPAR-γ, FAS, and perilipin A. The present invention demonstrates that 4-BPCA can be applied as a potential preventive and therapeutic agent for obesity and related diseases. Brief explanation of the drawing

[0032] Figure 1 shows the effects of 4-BPCA on lipid accumulation, triglyceride content, and growth during the differentiation of 3T3-L1 preadipocytes. Figure 1A shows that 3T3-L1 preadipocytes were induced to differentiate in induction medium containing MDI, insulin, and FBS in the presence or absence of various concentrations of 4-BPCA for 8 days (D8). Figure 1B shows the triglyceride content of control or 4-BPCA-treated cells measured using the AdipoRed assay on day D8. Figure 1C shows the viability of control or 4-BPCA-treated cells analyzed using the MTS assay on day 8. Figure 1D shows the chemical structure of 4-BPCA. Figure 2 shows the effects of 4-BPCA on the protein and mRNA expression and phosphorylation levels of C / EBP-α, PPAR-γ, and STAT-3 / 5 during the differentiation of 3T3-L1 preadipocytes. Figures 2A and 2B show the differentiation of 3T3-L1 preadipocytes in induction media containing MDI, insulin, and FBS with and without 2.5 μM of 4-BPCA for 2, 5, and 8 days, respectively. The results show the analysis of protein expression and phosphorylation levels measured using each antibody via Western blot analysis (Figure 2A). The results show the analysis of mRNA expression levels measured via RT-PCR (Figure 2B). Figure 3 shows the effects of 4-BPCA on the protein and mRNA expression of FAS, perilipin A, leptin, adiponectin, and RBP-4 during the differentiation of 3T3-L1 preadipocytes. Figures 3A and 3B show the differentiation of 3T3-L1 preadipocytes in induction media containing MDI, insulin, and FBS with and without 2.5 μM of 4-BPCA for 2, 5, and 8 days, respectively. Protein expression and phosphorylation levels were measured using Western blot analysis (Figure 3A). mRNA expression levels were measured and analyzed using RT-PCR (Figure 3B). Figure 4 shows the effects of 4-BPCA on lipid accumulation and growth during adipocyte differentiation. Figure 4A shows hASCs induced to differentiate using induction medium in the presence or absence of various concentrations of 4-BPCA for 12 days (D12). Figure 4B shows hASCs induced to differentiate using induction medium in the presence or absence of various concentrations of 4-BPCA. Figure 5 shows the effect of 4-BPCA on the protein expression levels of C / EBP-α, PPAR-γ, FAS, and perilipin A during adipocyte differentiation of hASCs. Specific details for implementing the invention

[0033] The present invention will be described in detail below.

[0034] The present invention provides a pharmaceutical composition for the prevention or treatment of obesity comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0035] [Chemical Formula 1]

[0036]

[0037] The term "4-BPCA" above refers to 4-biphenylcarboxylic acid, which is one of the caffeic acid derivatives. It is an effective compound that inhibits fat accumulation and adipocyte differentiation. In the present invention, it was confirmed that 4-BPCA reduced lipid accumulation in 3T3-L1 preadipocytes and human adipose stem cells (hASCs) in a concentration-dependent manner.

[0038] The term "pharmaceuticalally acceptable salt" in the present invention refers to a form of salt that can be used pharmaceutically, among substances in which cations and anions are bonded by electrostatic attraction. Typically, it may be a metal salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, or a salt with a basic or acidic amino acid. For example, metal salts may include alkali metal salts (sodium salts, potassium salts, etc.), alkaline earth metal salts (calcium salts, magnesium salts, barium salts, etc.), aluminum salts, etc.; salts with organic bases may include salts with triethylamine, pyridine, picoline, 2,6-rutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine, etc.; and salts with inorganic acids may include salts with hydrochloric acid, hydrobromide, nitric acid, sulfuric acid, phosphoric acid, etc. Salts with organic acids may include formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.; salts with basic amino acids may include arginine, lysine, ornithine, etc.; and salts with acidic amino acids may include aspartic acid, glutamic acid, etc.

[0039] For the purposes of the present invention, the above-mentioned pharmaceutically acceptable salt may be interpreted as an acid-added salt or a base-added salt of 4-PBCA suitable for the treatment of patients in whom the onset of drug-induced obesity is expected or in whom the disease has developed, but is not particularly limited thereto.

[0040] In the present invention, "prevention or treatment of obesity" refers to inhibiting obesity through actions such as weight loss, weight control, fat breakdown, inhibition of fat accumulation, inhibition of fat differentiation, and increase in metabolic activity, and may include all concepts of preventing or inhibiting obesity in addition to the above actions.

[0041] The term "prevention" above refers to any act of suppressing or delaying the onset of obesity, and the term "treatment" above refers to any act of improving or beneficially altering obesity through the administration of a pharmaceutical composition according to one aspect.

[0042] In one aspect, the "pharmaceutical composition" may be provided as a pharmaceutical composition comprising an active ingredient alone or comprising one or more pharmaceutically acceptable carriers, excipients, or diluents.

[0043] Specifically, the carrier may be, for example, a colloidal suspension, powder, saline solution, lipid, liposome, microsphere, or nano-spherical particle. These may form a complex with or be associated with a transport means and may be transported in vivo using a transport system known in the art, such as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption-enhancing substances, or fatty acids.

[0044] When the above pharmaceutical composition is formulated, it may be prepared using diluents or excipients such as commonly used lubricants, sweeteners, flavorings, emulsifiers, suspending agents, preservatives, fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration may include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the above pharmaceutical composition. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid formulations for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents like water and liquid paraffin. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. Witepsol, macrogol, Tween 61, cacao gelatin, laurin gelatin, glycerogelatin, etc. may be used as bases for suppositories, and known diluents or excipients may be used when manufactured in the form of ophthalmic preparations.

[0045] The above pharmaceutical composition may be administered parenterally or orally, such as external application to the skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intra-arterial injection, intramedullary injection, intracardiac injection, intrathecal injection, transdermal injection, nasal injection, enteral injection, local injection, sublingual injection, or intrathoracic injection.

[0046] The above pharmaceutical composition is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.

[0047] The above administration may be administered once a day or divided into several doses. For example, it may be administered every other day or once a week.

[0048] The above pharmaceutical composition may be provided by mixing it with a conventionally known pharmaceutical composition for the prevention or treatment of obesity or a newly developed pharmaceutical composition for the prevention or treatment of obesity. If the above pharmaceutical composition further comprises a pharmaceutical composition for the prevention or treatment of obesity, it is important that an amount is mixed such that the maximum effect can be obtained with the minimum amount without side effects, and this can be easily determined by a person skilled in the art.

[0049] In addition, in one aspect, the pharmaceutical composition may be administered alone or in combination with other obesity treatments. That is, the pharmaceutical composition may be administered in conjunction with a known composition or other obesity treatments having an effect of preventing or treating obesity, and may be administered simultaneously, separately, or sequentially, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above factors into consideration, and this can be easily determined by a person skilled in the art.

[0050] In one embodiment of the present invention, the composition may inhibit the differentiation of fat cells.

[0051] In another embodiment of the present invention, the composition may inhibit lipid accumulation within fat cells.

[0052] In another embodiment of the present invention, the composition may reduce the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, FAS and perilipin A, RBP-4 during the process of adipocyte differentiation.

[0053] The term "C / EBP-α (CCAAT-enhancer-binding protein alpha)" is a transcription factor that plays a crucial role in the process of adipocyte differentiation. This protein is expressed early in adipocyte differentiation and acts in conjunction with PPAR-γ to promote the expression of adipogenesis genes.

[0054] The term "PPAR-γ (Peroxisome proliferator-activated receptor gamma)" refers to a nuclear receptor protein that plays a key role in adipocyte differentiation and lipid metabolism. It interacts with C / EBP-α to regulate adipocyte differentiation and controls the expression of various genes related to fatty acid metabolism.

[0055] The term "FAS (Fatty Acid Synthase)" refers to an enzyme involved in fatty acid synthesis. This enzyme plays a crucial role in adipocytes and is essential for the process of fat accumulation. It is one of the adipogenic genes regulated by C / EBP-α and PPAR-γ.

[0056] The term "Perilipin A" refers to a protein located on the surface of lipid droplets that regulates their formation and breakdown. This protein plays an important role in regulating lipid storage and mobilization in adipocytes.

[0057] The term "RBP-4 (Retinol Binding Protein 4)" refers to a protein primarily produced in the liver that plays a role in transporting Vitamin A (retinol). Recent studies have revealed that RBP-4 is associated with insulin resistance and is known to be secreted in adipose tissue to influence metabolic regulation.

[0058] In addition, the present invention provides a pharmaceutical preparation for the prevention or treatment of obesity comprising the above pharmaceutical composition.

[0059] In one embodiment of the present invention, the formulation may be an injectable formulation, an infusion formulation, a spray formulation, a liquid formulation, or a patch formulation.

[0060] The term "injectable" above refers to a solution, suspension, emulsion, or solid sterile preparation that is administered directly into internal tissues or organs, such as subcutaneously, intramuscularly, or into blood vessels, or is dissolved in a solvent or suspended therein for use.

[0061] The term "injectable" above refers to a drug that is inserted into the body through the urethra, anus, vagina, etc., and dissolves due to body heat or secretions to produce its medicinal effect.

[0062] The term "spray" above refers to a medicine that is sprayed out like a mist using a device.

[0063] The term "liquid formulation" above refers to a pharmaceutical form that provides a drug in liquid form, and is a dosage form containing an active ingredient in liquid form.

[0064] The term "patch" above refers to a preparation designed to exert a continuous therapeutic effect when applied to the skin. Patches have the advantage of a lower risk of side effects, such as gastrointestinal or liver damage associated with oral medications, and can be administered to patients for whom oral administration is difficult. Furthermore, since they are absorbed directly into the bloodstream through the skin without undergoing hepatic metabolism, they can produce the same therapeutic effect without side effects at a lower dose compared to oral medications.

[0065] In addition, the present invention provides a health functional food composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0066] In one embodiment of the present invention, the composition may inhibit the differentiation of fat cells.

[0067] In another embodiment of the present invention, the composition may inhibit lipid accumulation within fat cells.

[0068] In another embodiment of the present invention, the composition may reduce the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, FAS and perilipin A, RBP-4 during the process of adipocyte differentiation.

[0069] The term "improvement" above may refer to any action that at least reduces parameters related to the condition being treated, for example, the severity of symptoms.

[0070] In one aspect, the above-mentioned health functional food may be used for the prevention or improvement of obesity, either simultaneously with or separately from a drug for treatment, before or after the onset of the disease.

[0071] In the above-mentioned health functional food, the active ingredient may be added directly to the food or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient may be appropriately determined according to its purpose of use (for prevention or improvement). Generally, when manufacturing food or beverages, the above-mentioned health functional food may be added in an amount of about 15% by weight or less, specifically about 10% by weight or less, with respect to the raw materials. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the above amount may be less than the above range.

[0072] The above-mentioned health functional food may be formulated into one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, and liquid formulations, by further including one or more of a carrier, a diluent, an excipient, and an additive. Foods to which a compound according to one aspect may be added include various types of food, powders, granules, tablets, capsules, syrups, beverages, gum, tea, vitamin complexes, health functional foods, etc.

[0073] Specific examples of the above carrier, excipient, diluent, and additive may be one or more selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0074] In addition to containing the active ingredient mentioned above, the above-mentioned health functional food may contain other ingredients as essential components without special limitations. For example, it may contain various flavoring agents or natural carbohydrates as additional ingredients, such as in ordinary beverages. Examples of the above-mentioned natural carbohydrates may be monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used. The proportion of the above-mentioned natural carbohydrates may be appropriately determined by the choice of a person skilled in the art.

[0075] In addition to the above, a health functional food according to one aspect may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. These ingredients may be used independently or in combination, and the proportion of these additives may also be appropriately selected by a person skilled in the art.

[0076] The above-mentioned health functional food may be provided in combination with a conventionally known health functional food for preventing or improving obesity or a newly developed health functional food for preventing or improving obesity. If the above-mentioned health functional food further includes a health functional food for preventing or improving obesity, it is important that an amount is mixed that can obtain maximum effect with a minimum amount without side effects, and this can be easily determined by a person skilled in the art.

[0077] In addition, the above-mentioned health functional food may be consumed alone or in combination with the above-mentioned health functional food for the prevention or improvement of obesity. The above-mentioned health functional food may be consumed in conjunction with a known composition having an effect of preventing or improving obesity or with other health functional foods for the prevention or improvement of obesity, and may be consumed simultaneously, separately, or sequentially, and may be consumed as a single or multiple times. It is important to consume an amount that obtains the maximum effect with the minimum amount without side effects by considering all of the above factors, and this can be easily determined by a person skilled in the art.

[0078] In addition, the present invention provides a quasi-drug composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0079] In one embodiment of the present invention, the composition may be formulated into an external preparation, a powder, a disinfectant, a toothpaste, an ointment, a lotion, an internal preparation, a wet wipe, a spray patch, a bandage, or a patch. However, it is not particularly limited thereto, and the method of formulation, dosage, method of use, and components of the quasi-drug may be appropriately selected by a person skilled in the art from the ordinary technology known in the relevant technical field.

[0080] In addition, when the composition of the present invention is used as a quasi-drug, one or more active ingredients exhibiting the same or similar functions as the 4-BPCA may be additionally included. For example, known ingredients having skin whitening, skin trouble improvement, anti-inflammatory, moisturizing, skin wrinkle improvement, or antioxidant activity may be additionally included; in this case, the skin whitening, skin trouble improvement, anti-inflammatory, moisturizing, skin wrinkle improvement, and antioxidant activities of the composition of the present invention may be further increased. When adding the above active ingredients, skin safety due to combined use, ease of formulation, and stability of the active ingredients may be considered. The above additional active ingredients may be included in an amount of 0.0001 to 10 weight % (w / w) relative to the total weight of the quasi-drug composition, and the above content range may be appropriately adjusted by a person skilled in the art considering skin safety, ease of formulation, etc. Furthermore, the quasi-drug composition of the present invention may additionally include other ingredients or substances that improve and prevent obesity in addition to the 4-BPCA.

[0081] In addition, the present invention provides a cosmetic composition for the prevention or improvement of obesity, comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) or a salt thereof as an active ingredient.

[0082] In one embodiment of the present invention, the composition may be formulated as a softening lotion, an astringent lotion, a nourishing lotion, a nourishing cream, a massage cream, a lotion, an essence, a pack, a skin adhesive patch, a skin adhesive gel, a powder, an ointment, a paste, a gel, a suspension, an emulsion, a spray, a cosmetic liquid, or a capsule.

[0083] The ingredients included in the cosmetic composition of the present invention include, in addition to 4-BPCA as an active ingredient, ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, colorants and fragrances, and carriers.

[0084] The cosmetic composition of the present invention may be prepared in any formulation conventionally manufactured in the art, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, emulsion, multi-emulsion, and liquid crystal, but is not limited thereto. More specifically, it may be prepared in the form of a nourishing cream, astringent lotion, softening lotion, lotion, essence, nourishing gel, or massage cream.

[0085] In the case where the formulation of the present invention is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component.

[0086] In the case where the formulation of the present invention is a powder or a spray, tos, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0087] When the formulation of the invention is a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0088] In the case where the formulation of the invention is a suspension, liquid diluents such as water, ethanol, or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth gum, etc. may be used as carrier components.

[0089] In the case where the formulation of the present invention is a cleansing agent containing a surfactant, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.

[0090] The present invention will be explained in more detail below through examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.

[0092] Examples

[0093] Experimental Materials and Methods

[0094] 1. Ingredients

[0095] 4-BPCA was developed as described in previously published papers (Bioorg Med Chem Lett. 2017;27:3374-7. Lee YH et al., Chem Pharm Bull (Tokyo). 1991;39:1736-45. Nakagawa Y et al.). Antibodies against C / EBP-α, PPAR-γ, phosphorylated (p)-STAT-3, p-STAT-5, STAT-3, and STAT-5 were purchased from Santa Cruz Biotechnology (Delaware, CA, USA). Antibodies against FAS were purchased from BD Bioscience (San Jose, CA, USA). Antibodies against perilipin A were purchased from BioVision (Milpitas, CA, USA). Antibodies against β-actin were purchased from Sigma (St. Louis, MO, USA).

[0096] 2. Cell Culture and Differentiation

[0097] 3T3-L1 mouse preadipocytes (ATCC, Manassas, VA, USA) were cultured in a growth medium containing Dulbecco's Modified Eagles' Medium (DMEM), 10% heat-inactivated fetal bovine serum (Gibco, Grand Island, NY, USA), and 1% penicillin-streptomycin (Welgene, Daegu, South Korea) at 37°C in humidified air (95% air, 5% CO2). To induce adipocyte differentiation, the medium was changed to DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Welgene), and cultured with a hormone cocktail (MDI) containing 0.5 mM IBMX (M), 0.5 mM dexamethasone (D), and 5 μg / mL insulin (I) at specified concentrations, either with or alone with 4-BPCA. On day 2 (D2), the first differentiation medium was replaced with DMEM supplemented with 10% FBS and 5 μg / mL insulin at specified doses, with or without 4-BPCA, for an additional 3 days (D5). The cells were supplied with DMEM containing 10% FBS with or without 4-BPCA for an additional 3 days (D8). The preadipocytes conditioned on D8 became mature adipocytes filled with LD.

[0098] hASCs were isolated from the abdominal subcutaneous adipose tissue of a female patient admitted to Keimyung University Dongsan Hospital in Daegu, South Korea. The Ethics Committee of Keimyung University Dongsan Hospital approved the invention protocol (No. 2021-02-063-018) and obtained informed consent from the patient. The isolated hASCs were further cultured in DMEM / nutrient mixture F-12 (DMEM / F-12) supplemented with 10% FBS and 1% penicillin-streptomycin, and the hASCs were cultured overnight in a 24-well plate supplemented with 10% FBS, 1% penicillin-streptomycin, and 0.25 μg / mL fungizone in DMEM / F-12. Adipocyte differentiation of hASCs was induced on day 0 (D0) using adipocyte differentiation medium (Zenbio, DM-2) for 7 days (D7). Then, the medium was changed to adipocyte maintenance medium (Zenbio, AM-1) and cultured for an additional 5 days (D12) in the absence or presence of 4-BPCA at the indicated concentration. On day 12, the hASCs became mature adipocytes filled with LD.

[0099] 3. Cell viability analysis

[0100] 3T3-L1 preadipocytes were seeded into 96-well plates and cultured overnight. Cells were treated with control solvent (DMSO; 0.1%) or 4-BPCA at specified concentrations for 8 days. Control or 4-BPCA-treated cells were cultured with [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) reagent (Promega, Madison, WI, USA) at 37°C for 1.5 hours, and absorbance was measured. Absorbance was measured at 490 nm using a Bio-Rad (Hercules, CA, USA) microplate reader.

[0101] 4. Cell count analysis

[0102] hASCs were seeded into 24-well plates and cultured overnight. Cells were treated with control solvent (DMSO; 0.1%) or 4-BPCA at indicated concentrations for 12 days. The number of viable cells was counted using the trypan blue exclusion method. For cell morphological analysis, conditioned cells treated with or without 4-BPCA were imaged using a phase-contrast microscope (Nikon Eclipse TS200, Nikon Corp., Tokyo, Japan).

[0103] 5. Oil Red O Dye

[0104] Lipids accumulated in adipocytes of control or 4-BPCA-treated 3T3-L1 cells and in hASCs of D8 and D12 were detected using Oil Red O staining. Cells were washed twice with phosphate-buffered saline (PBS), fixed with 10% formaldehyde for 2 hours, then washed with 60% isopropanol and dried. Fixed cells were stained with Oil Red O working solution (Sigma, St. Louis, MO, USA) for 1 hour at room temperature and washed twice with distilled water. Stained lipids were visualized using an optical microscope (Nikon, TS100, Tokyo, Japan).

[0105] 6. Measurement of intracellular triglyceride content

[0106] A commercially available AdipoRed test kit was used to evaluate the intracellular triglyceride content of control or 4-BPCA-treated 3T3-L1 preadipocytes differentiated and fermented for 8 days (D8) according to the manufacturer's instructions (Lonza, Basel, Switzerland). Fluorescence was measured on a Victor3 (Perkin Elmer, Waltham, MA, USA) with excitation at 485 nm and emission at 572 nm. The results are the average SE of three independent experiments.

[0107] 7. Preparation of whole-cell lysates

[0108] At specified times, conditioned 3T3-L1 preadipocytes or hASCs were washed twice with PBS and cultured in modified RIPA buffer [150 mM NaCl, 50 mM Tris-Cl (pH 7.4), 0.1% sodium deoxycholate, 0.25% sodium dodecyl sulfate, 1% Triton X-100, 1% Nonidet P-40, 1 mM EGTA, 1 mM EDTA, and protease inhibitor cocktail (1x)]. Whole cell lysates were collected and centrifuged at 12,000 rpm for 20 minutes at 4°C. The protein concentration of the whole cell lysates in the resulting supernatant was corrected using Bradford reagent (Bio-Rad, Hercules, CA, USA).

[0109] 8. Western blot analysis

[0110] Protein (50 μg whole cell lysate) was separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (MilliporeSigma, Burlington, MA, USA). The membrane was washed with TBS (10 mM Tris, 150 mM NaCl) containing 0.05% (vol / vol) Tween-20 (TBST) and further blocked with TBST containing 5% skim milk powder (MB cell, Seoul, Korea). The membranes were incubated with specific primary antibodies of C / EBP-α (1:1,000), PPAR-γ (1:1,000), STAT-3 (1:1,000), p-STAT-3 (1:1,000), STAT-5 (1:1,000), p-STAT-5 (1,000), FAS (1:2,000), perilipin A (1:2,000), or β-actin (1:10,000) at 4°C for 24 hours. Then, the membranes were incubated with a secondary antibody conjugated to horseradish peroxidase at RT for 2 hours, and all membranes were washed three times with TBST at room temperature. Finally, the membranes were developed using an enhanced chemiluminescence (ECL) reagent (Advansta, San Jose, CA, USA). The equivalent protein loading was determined using the expression levels of actin.

[0111] 9. Reverse Transcription Polymerase Chain Reaction (RT-PCR)

[0112] Cellular RNA was extracted from 3T3-L1 cells and hASCs treated with control or 4-BPCA at specified times using RNAzol-B (Tel-Test, Friendswood, TX). Then, 3 micrograms of total RNA were reverse transcribed using reverse transcriptase and random hexadeoxynucleotide primers. Single-stranded cDNA was used to amplify several genes, including C / EBP-α, PPAR-γ, FAS, perilipin A, and RBP-4, by PCR.

[0113] 10. Statistical Analysis

[0114] MTS analysis was performed in triplicate and repeated three times. Results were expressed as mean ± standard error (SE). One-way ANOVA was conducted using p-values ​​less than 0.05 to assess statistical significance. Cell number analysis was performed in triplicate and repeated three times. Results were expressed as mean ± SE. One-way ANOVA was used to evaluate significant differences among all test groups. All statistical analyses were found to be significant at p < 0.05.

[0116] Experimental results

[0117] 1. Analysis of the effect of 4-BPCA on inhibiting lipid accumulation and reducing triglyceride content during 3T3-L1 preadipocyte differentiation.

[0118] First, we investigated the effects of various concentrations of 4-BPCA on lipid accumulation during the adipocyte differentiation process of 3T3-L1 preadipocytes using Oil Red O staining. Next, we investigated whether 4-BPCA treatment regulates triglyceride content during 3T3-L1 preadipocyte differentiation using the AdipoRed assay.

[0119] As a result, as shown in Fig. 1A (top panel), on day 8 of differentiation (D8), a large number of lipid droplets (LDs) were formed and accumulated in 3T3-L1 cells compared to undifferentiated cells (D0). Notably, treatment with 4-BPCA strongly blocked the formation and accumulation of LDs in a dose-dependent manner. The lipid-reducing effect of 4-BPCA was further observed via phase-contrast microscopy (Fig. 1A, bottom panel). As shown in Fig. 1B, treatment with 2.5 or 5 μM of 4-BPCA significantly reduced triglyceride content in differentiated D8 3T3-L1 cells compared to undifferentiated cells D0. Furthermore, MTS analysis results, as indicated in Fig. 1C, showed that treatment with 4-BPCA at these doses did not cause cytotoxicity in differentiated D8 3T3-L1 cells. The chemical structure of 4-BPCA is shown in Fig. 1D. A concentration of 4-BPCA of 2.5 μM was selected for further invention due to its significant inhibitory effect on lipid accumulation and triglyceride levels.

[0121] 2. Analysis of the effects of 4-BPCA treatment on the reduction of protein and mRNA expression of C / EBP-α and PPAR-γ in 3T3-L1 preadipocyte differentiation

[0122] To understand the molecular mechanism of the lipid-reducing effect of 4-BPCA, Western blot analysis was used to investigate the effects of 2.5 μM treatment with 4-BPCA on the expression and phosphorylation levels of adipogenesis transcription factors during the adipocyte differentiation process of 3T3-L1 preadipocytes. Next, RT-PCR analysis was used to investigate whether the decrease in protein expression levels of C / EBP-α and PPAR-γ in 3T3-L1 cells by treatment with 2.5 μM 4-BPCA was due to transcriptional downregulation of C / EBP-α and PPAR-γ.

[0123] As a result, as shown in Figure 2A, 3T3-L1 cells treated with 2.5 μM of 4-BPCA showed significantly reduced protein expression levels of C / EBP-α and PPAR-γ compared to control cells of the same differentiation period in differentiation D2, D5, and D8. However, treatment with 2.5 μM of 4-BPCA had little effect on the phosphorylation and expression levels of STAT-3 and STAT-5 in 3T3-L1 cells of differentiation D2, D5, and D8 compared to control cells of the same differentiation period. As shown in Figure 2B, treatment with 2.5 μM of 4-BPCA reduced the mRNA expression levels of C / EBP-α and PPAR-γ in 3T3-L1 cells of differentiation D2, D5, and D8 compared to control cells of the same differentiation period.

[0125] 3. Analysis of the effects of 4-BPCA treatment on the reduction of protein and mRNA expression of FAS, perilipin A, and RBP-4 in 3T3-L1 preadipocyte differentiation

[0126] We investigated whether the expression of lipid synthesis or stabilization-related factors and adipokines is regulated when 3T3-L1 preadipocytes are treated with 2.5 μM of 4-BPCA during the adipocyte differentiation process using Western blot analysis and RT-PCR.

[0127] As a result, as shown in Figures 3A and B, treatment with 2.5 μM of 4-BPCA significantly reduced the protein and mRNA expression levels of FAS and perilipin A in differentiated D2, D5, and D8 3T3-L1 cells compared to control cells of the same differentiation period. Additionally, treatment with 2.5 μM of 4-BPCA reduced the mRNA expression levels of RBP-4 in differentiated D5 and D8 3T3-L1 cells compared to control cells of the same differentiation period. On the other hand, treatment with 2.5 μM of 4-BPCA did not significantly affect the mRNA expression levels of leptin and adiponectin in differentiated 3T3-L1 preadipocytes on the day of the experiment.

[0129] 4. Analysis of the Effects of 4-BPCA on Lipid Accumulation During Adipocyte Differentiation of hASCs

[0130] We investigated whether 4-BPCA treatment regulates lipid accumulation during the differentiation of human adipose stem cells into adipocytes.

[0131] As a result, as shown in Fig. 4A, Oil Red O staining (top panel) and microscopic observation (bottom panel) data showed high lipid accumulation in differentiated adipocytes at day 12 (D12) compared to undifferentiated hASCs at D0, respectively. Notably, treatment with 4-BPCA blocked lipid accumulation in differentiated adipocytes at D12 in a dose-dependent manner. Cell number analysis revealed that treatment with 4-BPCA at the applied dose did not exhibit cytotoxicity to hASCs differentiating at D12 (Fig. 4B).

[0133] 5. Analysis of the effect of 4-BPCA treatment on the reduction of C / EBP-α and PPAR-γ expression in the adipocyte differentiation of hASCs

[0134] We investigated the effect of 2.5 μM of 4-BPCA on the expression levels of C / EBP-α, PPAR-γFAS, and perilipin A during the adipocyte differentiation process of hASCs.

[0135] As a result, as can be seen in Figure 5, treatment with 2.5 μM of 4-BPCA significantly reduced the protein expression levels of C / EBP-α, PPAR-γFAS, and perilipin A in the adipocyte differentiation of hASCs at D7 and D12.

[0137] These experimental results indicate that the 4-BPCA of the present invention can be usefully utilized for the prevention and treatment of obesity by blocking differentiation into adipocytes and lipid accumulation in adipocytes.

[0139] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of obesity comprising, as an active ingredient, 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof, wherein the composition is characterized by reducing the expression levels of FAS and perilipin A during the process of adipocyte differentiation. [Chemical Formula 1] Claim 2 A pharmaceutical composition according to claim 1, wherein the composition inhibits the differentiation of adipocytes. Claim 3 A pharmaceutical composition according to claim 1, characterized in that the composition inhibits lipid accumulation within fat cells. Claim 4 A pharmaceutical composition according to claim 1, characterized in that the composition reduces the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, and RBP-4 during the process of adipocyte differentiation. Claim 5 A pharmaceutical preparation for the prevention or treatment of obesity comprising the pharmaceutical composition of claim 1. Claim 6 A pharmaceutical preparation according to claim 5, wherein the preparation is an injectable, injectable, sprayable, liquid, or patchable formulation. Claim 7 A health functional food composition for the prevention or improvement of obesity comprising 4-BPCA ((E)-N-(4-Butylphenyl)-3-(3,4-dihydroxyphenyl)acrylamide) represented by the following chemical formula 1 or a salt thereof as an active ingredient, wherein the composition is characterized by reducing the expression levels of FAS and perilipin A during the process of adipocyte differentiation. [Chemical Formula 1] Claim 8 A health functional food composition according to claim 7, wherein the composition inhibits the differentiation of adipocytes. Claim 9 A health functional food composition according to claim 7, characterized in that the composition inhibits lipid accumulation within fat cells. Claim 10 A health functional food composition according to claim 7, characterized in that the composition reduces the expression level of one or more factors selected from the group consisting of C / EBP-α, PPAR-γ, and RBP-4 during the process of adipocyte differentiation. Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 delete

Citation Information

Patent Citations

  • Caffeic acid derivatives and compositions comprising the same as an active ingredient

    KR1020080030938A

  • Composition for anti-obesity comprising dihydrocaffeic acid

    KR1020220036304A

  • Food composition for obesity prevention or pharmaceutical composition for obesity treatment containing caffeic acid phenethyl ester

    KR1020110021252A

  • Skin Whitening Composition Comprising Caffeic Acid Derivatives as the Active Ingredients

    KR1020140124987A